SCHEDULE 13D/A: Cevian Capital II GP Boosts Stake in Smith & Nephew PLC to 7.49%
Beneficial Ownership Update
Cevian Capital II GP Limited has increased its beneficial ownership in medical technology firm Smith & Nephew PLC to 7.49% of outstanding ordinary shares, representing an aggregate investment of approximately $815 million.
Summary
- Cevian Capital II GP Limited, the Reporting Person, has filed Amendment No. 2 to its Schedule 13D regarding its beneficial ownership in Smith & Nephew PLC.
- The Reporting Person now beneficially owns an aggregate of 65,480,254 Ordinary Shares of Smith & Nephew PLC.
- This stake represents 7.49% of the Issuer's Ordinary Shares, calculated based on 874,396,080 shares outstanding as of January 31, 2025.
- The total aggregate consideration for these shares, including brokerage commissions, is approximately USD $814,935,555.
- The purchases were funded out of the Cevian Funds' general working capital and were made using British Pounds, with a conversion rate of USD $1.26165 for each GBP 1.00 used for reporting purposes.
- Transactions in Ordinary Shares by the Reporting Person since the filing of Amendment No. 1 are detailed in Schedule B, with purchases occurring between December 27, 2024, and February 18, 2025, at prices ranging from $12.35 to $12.99 per share.
Sentiment
Score: 7
Explanation: The increased stake by a prominent activist investor like Cevian Capital is generally perceived positively by the market, indicating potential for value creation and strategic changes, although the filing itself is purely an ownership disclosure.
Positives
- The increased stake by Cevian Capital, a prominent activist investor, signals confidence in Smith & Nephew PLC's value and potential for future improvements.
- A significant institutional investment of approximately $815 million demonstrates a strong commitment to the company.
Future Outlook
NA
Industry Context
Smith & Nephew PLC operates in the global medical technology industry, specializing in orthopaedics, advanced wound management, and sports medicine. Cevian Capital's increased stake in the company suggests a belief in the potential for operational or strategic improvements within the medical technology sector, which is characterized by innovation, regulatory complexities, and competitive pressures.
Stakeholder Impact
- Shareholders: May view the increased stake by Cevian Capital positively, anticipating potential strategic changes or improved governance that could enhance shareholder value.
Key Dates
| Date | Description |
|---|---|
| 2024-07-09 | Original Schedule 13D filed with the Securities and Exchange Commission. |
| 2024-12-27 | Earliest trade date for Ordinary Shares purchased by the Reporting Person since Amendment No. 1. |
| 2025-01-31 | Date as of which 874,396,080 Ordinary Shares were reported outstanding in the Issuer's Form 6-K. |
| 2025-02-03 | Date of Issuer's Report of Foreign Private Issuer on Form 6-K filed with the SEC. |
| 2025-02-14 | Date of event which requires filing of this statement (Amendment No. 2). |
| 2025-02-18 | Latest trade date for Ordinary Shares purchased by the Reporting Person since Amendment No. 1. |
| 2025-02-19 | Date of signature for Amendment No. 2. |
Recommendation
holdKeywords
Smith & Nephew PLC, Cevian Capital, Schedule 13D, Beneficial Ownership, Institutional Investment, Equity Stake, Medical Technology, Healthcare, SNN
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.